MX346002B - Anticuerpos anti-vegf y sus usos. - Google Patents
Anticuerpos anti-vegf y sus usos.Info
- Publication number
- MX346002B MX346002B MX2014001638A MX2014001638A MX346002B MX 346002 B MX346002 B MX 346002B MX 2014001638 A MX2014001638 A MX 2014001638A MX 2014001638 A MX2014001638 A MX 2014001638A MX 346002 B MX346002 B MX 346002B
- Authority
- MX
- Mexico
- Prior art keywords
- vegf antibodies
- vegf
- antibodies
- overproduction
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a anticuerpos dirigidos al factor de crecimiento endotelial vascular ("VEGF") y a los usos de tales anticuerpos, por ejemplo para tratar enfermedades asociadas con actividad y/o sobreproducción de VEGF.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21800509P | 2009-06-17 | 2009-06-17 | |
PCT/US2010/039029 WO2010148223A2 (en) | 2009-06-17 | 2010-06-17 | Anti-vegf antibodies and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
MX346002B true MX346002B (es) | 2017-03-01 |
Family
ID=42543312
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001638A MX346002B (es) | 2009-06-17 | 2010-06-17 | Anticuerpos anti-vegf y sus usos. |
MX2011013781A MX2011013781A (es) | 2009-06-17 | 2010-06-17 | Anticuerpos anti-vegf y sus usos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011013781A MX2011013781A (es) | 2009-06-17 | 2010-06-17 | Anticuerpos anti-vegf y sus usos. |
Country Status (25)
Country | Link |
---|---|
US (1) | US9079953B2 (es) |
EP (2) | EP2443150B1 (es) |
JP (1) | JP5785941B2 (es) |
KR (1) | KR20120034739A (es) |
CN (1) | CN102482349B (es) |
AU (1) | AU2010262836B2 (es) |
BR (1) | BRPI1012321A8 (es) |
CA (1) | CA2765755C (es) |
CL (1) | CL2011003182A1 (es) |
CO (1) | CO6480962A2 (es) |
CR (1) | CR20110653A (es) |
EC (1) | ECSP12011584A (es) |
ES (2) | ES2534355T3 (es) |
GT (1) | GT201100326A (es) |
HK (1) | HK1211961A1 (es) |
IL (2) | IL216835A0 (es) |
MX (2) | MX346002B (es) |
NZ (1) | NZ596837A (es) |
PE (1) | PE20120622A1 (es) |
RU (1) | RU2567639C2 (es) |
SG (2) | SG177265A1 (es) |
TW (1) | TWI510248B (es) |
UA (1) | UA104626C2 (es) |
WO (1) | WO2010148223A2 (es) |
ZA (1) | ZA201109098B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
US20130310281A1 (en) * | 2011-02-02 | 2013-11-21 | Glaxo Group Limited | Novel antigen binding proteins |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
MX358864B (es) * | 2011-04-12 | 2018-09-06 | Gangagen Inc | Polipeptidos antibacterianos quimericos. |
LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
AR092630A1 (es) * | 2012-09-19 | 2015-04-29 | Genentech Inc | Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas |
WO2014052713A2 (en) | 2012-09-27 | 2014-04-03 | Massachusetts Institute Of Technology | Her2-and vegf-a-binding proteins with enhanced stability |
KR101279895B1 (ko) * | 2012-10-24 | 2013-06-28 | 주식회사 진흥기공 | 유체 이송용 덕트에 결합 사용되는 댐퍼의 이중 브레이드 밀폐 장치 |
US20140154255A1 (en) * | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
EA031025B1 (ru) | 2012-12-21 | 2018-11-30 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные с ними композиции и способы |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
MX368142B (es) * | 2013-04-30 | 2019-09-20 | Intas Pharmaceuticals Ltd | Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. |
CA2915255A1 (en) * | 2013-07-12 | 2015-01-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
US10702608B2 (en) | 2013-09-08 | 2020-07-07 | Kodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugates |
EP3134115A4 (en) | 2014-04-25 | 2017-10-25 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US10718781B2 (en) | 2014-07-14 | 2020-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method for identifying epitope on protein |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
CN108148135B (zh) * | 2015-01-06 | 2020-06-12 | 珠海亿胜生物制药有限公司 | 抗vegf抗体 |
SG11201805420SA (en) * | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
JP2019515027A (ja) * | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療 |
AU2017248731A1 (en) * | 2016-04-15 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
CN106039309B (zh) * | 2016-06-30 | 2024-04-19 | 中国人民解放军总医院第一附属医院 | 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用 |
JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のaav媒介送達 |
EP3863657A4 (en) * | 2018-10-12 | 2022-07-20 | Trican Biotechnology Co., Ltd | BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF |
CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
CN111363038A (zh) * | 2020-03-26 | 2020-07-03 | 北京纽安博生物技术有限公司 | 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用 |
CN111808191A (zh) * | 2020-05-11 | 2020-10-23 | 廊坊天光生物技术有限公司 | 一种用于检测血清中vegf含量的抗体对及其用途 |
JP2023551533A (ja) | 2020-12-01 | 2023-12-08 | アコーオス インコーポレイテッド | 前庭神経鞘腫関連症状を治療するための抗vegf抗体構築物及び関連する方法 |
WO2022183418A1 (zh) * | 2021-03-04 | 2022-09-09 | 百奥泰生物制药股份有限公司 | 抗vegf抗体制剂 |
WO2023150142A1 (en) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
SI0971959T1 (sl) | 1997-04-07 | 2006-06-30 | Genentech Inc | Humanizirana protitelesa in postopki za tvorbo humaniziranih protiteles |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US7365166B2 (en) * | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ATE384792T1 (de) * | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
SI1135498T1 (sl) | 1998-11-18 | 2008-06-30 | Genentech Inc | Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi |
IL143596A0 (en) * | 1998-12-22 | 2002-04-21 | Genentech Inc | Vascular endothelial cell growth factor antagonists and uses thereof |
US6979559B2 (en) * | 2000-10-12 | 2005-12-27 | Marical, Inc. | Polyvalent cation-sensing receptor in atlantic salmon |
CA2430249A1 (en) * | 2000-12-14 | 2002-06-20 | Genentech, Inc. | Bacterial host strains |
DK1356052T3 (da) | 2000-12-14 | 2008-12-08 | Genentech Inc | Produktion af hele antistoffer i prokaryotiske celler |
US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
CA2369893A1 (en) | 2001-02-12 | 2002-08-12 | Warner-Lambert Company | Vegf responsive cell-based assay for determining vegf bioactivity |
US20030022240A1 (en) * | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
US20040010376A1 (en) * | 2001-04-17 | 2004-01-15 | Peizhi Luo | Generation and selection of protein library in silico |
US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
AU2003216250A1 (en) * | 2002-02-11 | 2003-09-04 | Genentech, Inc. | Antibody variants with faster antigen association rates |
CA2485732A1 (en) * | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
WO2004065417A2 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
KR20160114727A (ko) * | 2003-05-30 | 2016-10-05 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
PT3095793T (pt) * | 2003-07-28 | 2020-05-04 | Genentech Inc | Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
AU2005285347A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
BRPI0516350A (pt) | 2004-10-12 | 2008-09-02 | Amprotein Corp | proteìna de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de produção de um polipeptìdio, composição, método de modulação de uma imunoresposta em um indivìduo, método para aumentar a meia vida de uma proteìna recombinante em um indivìduo e método para aumentar a eficácia de uma proteìna recombinante em um indivìduo e método de aplicação de uma proteìna terapêutica a um sìtio alvo em um indivìduo |
MX2007004374A (es) * | 2004-10-12 | 2008-01-29 | Amprotein Corp | Proteina quimerica. |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
US20080207467A1 (en) * | 2005-03-03 | 2008-08-28 | Xencor, Inc. | Methods for the design of libraries of protein variants |
JP2009515516A (ja) * | 2005-11-14 | 2009-04-16 | バイオレン・インク | 推定成熟cdrのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化 |
WO2007059336A1 (en) | 2005-11-18 | 2007-05-24 | Nextrom Oy | Method and apparatus for manufacturing water-free optical fiber preforms |
JP2009516513A (ja) * | 2005-11-21 | 2009-04-23 | ラボラトワール セローノ ソシエテ アノニム | ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用 |
JP2009525274A (ja) * | 2006-01-23 | 2009-07-09 | ジョゼフ・ピー・エリコ | 標的薬物開発の方法および組成物 |
ES2603399T3 (es) * | 2006-07-10 | 2017-02-27 | Esbatech, An Alcon Biomedical Research Unit Llc | Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales |
US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
ES2751022T3 (es) * | 2007-07-09 | 2020-03-30 | Genentech Inc | Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos |
EP2280997A2 (en) * | 2008-04-18 | 2011-02-09 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
-
2010
- 2010-06-17 JP JP2012516307A patent/JP5785941B2/ja not_active Expired - Fee Related
- 2010-06-17 US US12/817,800 patent/US9079953B2/en not_active Expired - Fee Related
- 2010-06-17 KR KR1020127001157A patent/KR20120034739A/ko not_active Application Discontinuation
- 2010-06-17 ES ES10725590.3T patent/ES2534355T3/es active Active
- 2010-06-17 AU AU2010262836A patent/AU2010262836B2/en not_active Ceased
- 2010-06-17 SG SG2011093473A patent/SG177265A1/en unknown
- 2010-06-17 MX MX2014001638A patent/MX346002B/es unknown
- 2010-06-17 CA CA2765755A patent/CA2765755C/en not_active Expired - Fee Related
- 2010-06-17 NZ NZ596837A patent/NZ596837A/en not_active IP Right Cessation
- 2010-06-17 UA UAA201114515A patent/UA104626C2/ru unknown
- 2010-06-17 CN CN201080027121.5A patent/CN102482349B/zh not_active Expired - Fee Related
- 2010-06-17 WO PCT/US2010/039029 patent/WO2010148223A2/en active Application Filing
- 2010-06-17 MX MX2011013781A patent/MX2011013781A/es active IP Right Grant
- 2010-06-17 EP EP10725590.3A patent/EP2443150B1/en active Active
- 2010-06-17 ES ES14197237.2T patent/ES2656446T3/es active Active
- 2010-06-17 PE PE2011002096A patent/PE20120622A1/es not_active Application Discontinuation
- 2010-06-17 SG SG10201403327WA patent/SG10201403327WA/en unknown
- 2010-06-17 RU RU2011150916/10A patent/RU2567639C2/ru not_active IP Right Cessation
- 2010-06-17 TW TW099119749A patent/TWI510248B/zh not_active IP Right Cessation
- 2010-06-17 BR BRPI1012321A patent/BRPI1012321A8/pt not_active IP Right Cessation
- 2010-06-17 EP EP14197237.2A patent/EP2894167B1/en not_active Not-in-force
-
2011
- 2011-12-06 CR CR20110653A patent/CR20110653A/es unknown
- 2011-12-07 IL IL216835A patent/IL216835A0/en not_active IP Right Cessation
- 2011-12-09 ZA ZA2011/09098A patent/ZA201109098B/en unknown
- 2011-12-15 CL CL2011003182A patent/CL2011003182A1/es unknown
- 2011-12-16 GT GT201100326A patent/GT201100326A/es unknown
- 2011-12-28 CO CO11179622A patent/CO6480962A2/es not_active Application Discontinuation
-
2012
- 2012-01-09 EC ECSP12011584 patent/ECSP12011584A/es unknown
-
2015
- 2015-06-23 IL IL239604A patent/IL239604A/en not_active IP Right Cessation
- 2015-12-30 HK HK15112838.4A patent/HK1211961A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011013781A (es) | Anticuerpos anti-vegf y sus usos. | |
MX2015006859A (es) | Anticuerpos anti-vegf y sus usos. | |
MX2011010908A (es) | Anticuerpos anti-tnf-alfa y sus usos. | |
TN2012000040A1 (en) | High affinity human antibodies to human angiopoietin -2 | |
WO2011113019A3 (en) | Ctla4 proteins and their uses | |
TN2012000555A1 (en) | Antibodies to human gdf8 | |
WO2010032059A3 (en) | Antibodies directed to cd105 and uses thereof | |
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
JO2576B1 (en) | Antibodies | |
MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
WO2011143318A3 (en) | Anti-fgfr2 antibodies | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
MX2013007379A (es) | Mutantes tipo papel lija de bacillus y metodos de uso de los mismos para mejorar el crecimiento vegetal, promover la salud de plantas y controlar enfermedades y plagas. | |
WO2012019168A3 (en) | Engineered nucleic acids and methods of use thereof | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
WO2009013543A3 (en) | Targeted binging agents directed to kdr and uses thereof - 035 | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
EA201390704A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201290360A1 (ru) | Гуманизированные антитела против il-22ra человека | |
GB201109238D0 (en) | Antibodies | |
GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
UA107836C2 (uk) | Метод лікування хвороби альцгеймера | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
WO2010072740A3 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF | |
MX2013011629A (es) | Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina. |